Vamikibart Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Vamikibart Growth

1. Significant Unmet Need in Uveitic Macular Edema

A major growth driver is the high unmet medical need in UME. UME results from inflammation caused by uveitis and leads to fluid accumulation in the macula, often causing progressive vision loss. Uveitis is responsible for 10-20% of blindness in the United States and Europe and up to 25% of blindness in developing countries, highlighting the substantial disease burden.

Current treatment mainly relies on corticosteroids, which are associated with serious side effects such as cataracts, glaucoma, and elevated intraocular pressure.

Because of these limitations, there is strong demand for non-steroidal disease-modifying therapies, creating a favorable commercial opportunity for vamikibart.

2. First Targeted Non-Steroidal Therapy for UME

Vamikibart is a humanized monoclonal antibody targeting interleukin-6 (IL-6), a key cytokine involved in inflammatory pathways responsible for retinal swelling and vision loss.

Key differentiation factors include:

• Direct inhibition of IL-6-mediated inflammation
• Potential steroid-sparing treatment option for chronic ocular inflammation
• Intravitreal administration delivering therapy directly to retinal tissues

If approved, it could become the first targeted non-steroidal biologic therapy for UME, which would give it a strong competitive advantage in the ophthalmology market.

3. Positive Phase III Clinical Trial Results Supporting Approval Potential

Late-stage clinical trials have demonstrated encouraging efficacy signals. In the global Phase III MEERKAT study, vamikibart showed statistically significant improvements in vision compared with sham treatment.

Key results include:

• 36.9% of patients achieved >=15-letter improvement in visual acuity with the 1 mg dose compared with placebo.
• Average best-corrected visual acuity improved by +12.8 letters.
• Macular thickness decreased by ~196 µm, indicating substantial reduction in retinal swelling.

Across both pivotal trials, patients treated with vamikibart demonstrated rapid and clinically meaningful improvements in visual acuity and retinal thickness, supporting its therapeutic potential.

Strong Phase III data significantly increase the likelihood of regulatory approval and commercial success.

4. Favorable Regulatory Designations and Development Momentum

Vamikibart has received orphan drug designation in both the United States and the European Union for the treatment of non-infectious uveitis, which provides development incentives such as market exclusivity and regulatory support.

These incentives typically enable:

• Faster regulatory pathways
• Reduced development costs
• Extended commercial exclusivity

Such regulatory advantages can improve long-term revenue potential once the therapy reaches the market.

5. Expansion Potential into Additional Retinal Diseases

Another important growth driver is the potential expansion of vamikibart into additional retinal disorders beyond UME. Clinical programs are also exploring the therapy in Diabetic Macular Edema, where inflammation and vascular leakage play a major role.

If successful, this expansion could significantly increase the total addressable market, as diabetic macular edema represents a much larger global patient population compared with UME.

Vamikibart Recent Developments

• In October 2025, Roche announced results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1 mg) compared with a sham procedure that mimics intravitreal (IVT) injections in people with uveitic macular edema (UME). UME is characterised by the buildup of fluid in the macula due to uveitis, an inflammatory condition of the eye, that can result in vision loss. Across both studies, the primary and secondary endpoint data support the potential for rapid improvements in vision and reductions in macular thickness (swelling in the back of the eye due to retinal fluid) with vamikibart treatment.

"Vamikibart Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Vamikibart for potential indication like Retinal oedema in the 7MM. A detailed picture of Vamikibart's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Vamikibart for potential indications. The Vamikibart market report provides insights about Vamikibart's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Vamikibart performance, future market assessments inclusive of the Vamikibart market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Vamikibart sales forecasts, along with factors driving its market.

Vamikibart Drug Summary

Vamikibart (RG6179, RO7200220) is an investigational humanized IgG2 kappa monoclonal antibody developed by Genentech (Roche) that specifically targets and inhibits interleukin-6 (IL-6), a key pro-inflammatory cytokine driving ocular inflammation. By blocking IL-6 binding to its receptor, it disrupts downstream inflammatory signaling pathways responsible for vascular leakage and retinal swelling, thereby reducing macular edema and improving best-corrected visual acuity (BCVA) in conditions like uveitic macular edema (UME) and diabetic macular edema (DME). Engineered for intravitreal (IVT) administration to achieve targeted ocular delivery with minimal systemic exposure, it has shown rapid vision gains and edema resolution in Phase I (DOVETAIL) and promising Phase III trials, positioning it as a first-in-class non-steroidal biologic for these retinal disorders. The report provides Vamikibart's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Vamikibart Market Report

The report provides insights into:

• A comprehensive product overview including the Vamikibart MoA, description, dosage and administration, research and development activities in potential indication like Retinal oedema.
• Elaborated details on Vamikibart regulatory milestones and other development activities have been provided in Vamikibart market report.
• The report also highlights Vamikibart's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Vamikibart market report also covers the patents information, generic entry and impact on cost cut.
• The Vamikibart market report contains current and forecasted Vamikibart sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Vamikibart market report also features the SWOT analysis with analyst views for Vamikibart in potential indications.

Methodology:

The Vamikibart market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Vamikibart Analytical Perspective by DelveInsight

• In-depth Vamikibart Market Assessment

This Vamikibart sales market forecast report provides a detailed market assessment of Vamikibart for potential indication like Retinal oedema in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Vamikibart sales data uptil 2034.

• Vamikibart Clinical Assessment

The Vamikibart market report provides the clinical trials information of Vamikibart for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Vamikibart Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Vamikibart Market Potential & Revenue Forecast

• Projected market size for the Vamikibart and its key indications
• Estimated Vamikibart sales potential (Vamikibart peak sales forecasts)
• Vamikibart Pricing strategies and reimbursement landscape

Vamikibart Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Vamikibart Market positioning compared to existing treatments
• Vamikibart Strengths & weaknesses relative to competitors

Vamikibart Regulatory & Commercial Milestones

• Vamikibart Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Vamikibart Clinical Differentiation

• Vamikibart Efficacy & safety advantages over existing drugs
• Vamikibart Unique selling points

Vamikibart Market Report Highlights

• In the coming years, the Vamikibart market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Vamikibart companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Vamikibart's dominance.
• Other emerging products for Retinal oedema are expected to give tough market competition to Vamikibart and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Vamikibart in potential indications.
• Analyse Vamikibart cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Vamikibart sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Vamikibart in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Vamikibart? How strong is Vamikibart's clinical and commercial performance?
• What is Vamikibart's clinical trial status in each individual indications such as Retinal oedema and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Vamikibart Manufacturers?
• What are the key designations that have been granted to Vamikibart for potential indications? How are they going to impact Vamikibart's penetration in various geographies?
• What is the current and forecasted Vamikibart market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Vamikibart in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Vamikibart for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Vamikibart? What is the duration of therapy and what are the geographical variations in cost per patient?